Clinical Trials Logo

Lymphoma, T-Cell clinical trials

View clinical trials related to Lymphoma, T-Cell.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 6

NCT ID: NCT02881749 Not yet recruiting - Mycosis Fungoides Clinical Trials

Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The clinical efficacy of mechlorethamine gel (Valchlor) as a maintenance therapy after low dose total skin electron beam therapy (TSEBT) for the treatment mycosis fungoides cutaneous T-cell lymphoma will be evaluated in this study. Subjects will be treated with low dose TSEBT (12 Gy total) over a period of two weeks. After a 30 day observation period and confirmation that their disease stage has been downgraded to IA or IB, subjects will use Valchlor as a maintenance therapy over the course of one year. The efficacy of Valchlor as a maintenance drug will be followed clinically through Modified Severity Weight Assessment Tool (mSWAT) and percent body surface area measurements (%BSA). Furthermore, subjects will be followed histopathologically through skin biopsies performed at the screening visit, immediately after observation period, one month after the start of the maintenance period, and twelve months after the start of the maintenance period (4 biopsies total).

NCT ID: NCT02856997 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.

NCT ID: NCT02844881 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The study is aimed to evaluate the efficacy and safety of Apatinib and MASCT in patients with advanced solid tumors.

NCT ID: NCT02229682 Not yet recruiting - Lymphoma, Clinical Trials

Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy

Start date: October 2014
Phase: Phase 2
Study type: Interventional

This study is to make sure whether reduced-dose radiation treatment is sufficient to control the disease in patients with early-staged extranodal nasal-type NK/T-cell lymphoma, who have got complete remission tumor after chemotherapy in a new and more effective asparaginase-based GELOX regimen

NCT ID: NCT01645293 Not yet recruiting - Clinical trials for CD30 Positive Transformed Mycosis Fungoides

Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides

TECLA
Start date: n/a
Phase: Phase 1
Study type: Interventional

Patients with cutaneous CD30 positive lymphoma will receive systemical and topical treatment with their own genetically modified T cells. Treatment evaluation consists of assessment of safety and preliminary evidence of response.

NCT ID: NCT00299351 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma (PTCL)

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

Start date: n/a
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on prior Gloucester-sponsored depsipeptide clinical trials, and in the opinion of their physician/ investigator might benefit from continued treatment with depsipeptide